News Release

December 10, 2024

Perseus Proteomics, Inc.
President & CEO: Takuya Yokokawa
e-mail: ir@ppmx.com

Announcement of Presentation of PPMX-T003 Phase I of Polycythemia Vera at 66th ASH Annual Meeting and Exposition

Perseus Proteomics Inc. is pleased to announce that the report of the phase I clinical trial of PPMX-T003, an anti-transferrin receptor 1 (TfR1) antibody, among polycythemia vera (PV) patients was presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.

Title: Phase I Safety Study of Anti-Transferrin Receptor 1 Antibody (PPMX-T003) in Patients with Polycythemia Vera and Erythrocythemia

Abstract Number: 4542

Outline: PPMX-T003, an anti-TfR1 antibody, targets TfR1, which is related to iron uptake of cells. In the phase I clinical trial among 6 polycythemia vera (PV) patients, the primary objective was to confirm safety and pharmacokinetics of PPMX-T003. The initial dosage was set at 0.25 mg/kg, with an optional escalation up to 1.0 mg/kg for additional administration if the initial effect proves insufficient. Among the five subjects excluding the sixth subject who cancelled the trial due to personal reasons, a 12-week period without the need for phlebotomy was achieved. Side effects levels were the same as those among healthy volunteers, with no serious adverse effects observed. Also, efficacy was indicated with RBC parameters including hematocrit and hemoglobin.

■ About Perseus Proteomics

Perseus Proteomics (HQ: Chuo-ku, Tokyo) is a biotech venture established in February 2001, aiming to develop novel antibody therapeutic drugs mainly for cancer. PPMX-T003 is a first-in-class TfR1 blocking antibody obtained from the library rich in diversity using the ICOS screening method (patent No. JPB4870348). The Company has been developing PPMX-T002, RI labelled antibody, and PPMX-T004, antibody drug conjugate (ADC), as well.

https://www.ppmx.com/en/

END